Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice

Graciela Andrei, Don B. Gammon, Pierre Fiten, Erik De Clercq, Ghislain Opdenakker, Robert Snoeck, David H. Evans

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC)] is recognized as a promising drug for the treatment of poxvirus infections, but drug resistance can arise by a mechanism that is poorly understood. We show here that in vitro selection for high levels of resistance to HPMPC produces viruses encoding two substitution mutations in the virus DNA polymerase (E9L) gene. These mutations are located within the regions of the gene encoding the 3′-5′ exonuclease (A314T) and polymerase (A684V) catalytic domains. These mutant viruses exhibited cross-resistance to other nucleoside phosphonate drugs, while they remained sensitive to other unrelated DNA polymerase inhibitors. Marker rescue experiments were used to transfer A314T and/or A684V alleles into a vaccinia virus Western Reserve strain. Either mutation alone could confer a drug resistance phenotype, although the degree of resistance was significantly lower than when virus encoded both mutations. The A684V substitution, but not the A314T change, also conferred a spontaneous mutator phenotype. All of the HPMPC-resistant recombinant viruses exhibited reduced virulence in mice, demonstrating that these E9L mutations are inextricably linked to reduced fitness in vivo. HPMPC, at a dose of 50 mg/kg of body weight/day for 5 days, still protected mice against intranasal challenge with the drug-resistant virus with A314T and A684V mutations. Our studies show that proposed drug therapies offer a reasonable likelihood of controlling orthopoxvirus infections, even if the viruses encode drug resistance markers.

Original languageEnglish (US)
Pages (from-to)9391-9401
Number of pages11
JournalJournal of Virology
Volume80
Issue number19
DOIs
StatePublished - Oct 1 2006

Fingerprint

Vaccinia virus
Virulence
virulence
Viruses
cytosine
viruses
Mutation
mutation
Cytosine
mice
Drug Resistance
drug resistance
DNA-directed DNA polymerase
Poxviridae Infections
drug therapy
Orthopoxvirus
Pharmaceutical Preparations
Nucleic Acid Synthesis Inhibitors
Phenotype
Poxviridae

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Andrei, G., Gammon, D. B., Fiten, P., De Clercq, E., Opdenakker, G., Snoeck, R., & Evans, D. H. (2006). Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. Journal of Virology, 80(19), 9391-9401. https://doi.org/10.1128/JVI.00605-06

Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. / Andrei, Graciela; Gammon, Don B.; Fiten, Pierre; De Clercq, Erik; Opdenakker, Ghislain; Snoeck, Robert; Evans, David H.

In: Journal of Virology, Vol. 80, No. 19, 01.10.2006, p. 9391-9401.

Research output: Contribution to journalArticle

Andrei, G, Gammon, DB, Fiten, P, De Clercq, E, Opdenakker, G, Snoeck, R & Evans, DH 2006, 'Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice', Journal of Virology, vol. 80, no. 19, pp. 9391-9401. https://doi.org/10.1128/JVI.00605-06
Andrei, Graciela ; Gammon, Don B. ; Fiten, Pierre ; De Clercq, Erik ; Opdenakker, Ghislain ; Snoeck, Robert ; Evans, David H. / Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. In: Journal of Virology. 2006 ; Vol. 80, No. 19. pp. 9391-9401.
@article{cefba2c6c88947a18b13b66b54f614a0,
title = "Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice",
abstract = "Cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC)] is recognized as a promising drug for the treatment of poxvirus infections, but drug resistance can arise by a mechanism that is poorly understood. We show here that in vitro selection for high levels of resistance to HPMPC produces viruses encoding two substitution mutations in the virus DNA polymerase (E9L) gene. These mutations are located within the regions of the gene encoding the 3′-5′ exonuclease (A314T) and polymerase (A684V) catalytic domains. These mutant viruses exhibited cross-resistance to other nucleoside phosphonate drugs, while they remained sensitive to other unrelated DNA polymerase inhibitors. Marker rescue experiments were used to transfer A314T and/or A684V alleles into a vaccinia virus Western Reserve strain. Either mutation alone could confer a drug resistance phenotype, although the degree of resistance was significantly lower than when virus encoded both mutations. The A684V substitution, but not the A314T change, also conferred a spontaneous mutator phenotype. All of the HPMPC-resistant recombinant viruses exhibited reduced virulence in mice, demonstrating that these E9L mutations are inextricably linked to reduced fitness in vivo. HPMPC, at a dose of 50 mg/kg of body weight/day for 5 days, still protected mice against intranasal challenge with the drug-resistant virus with A314T and A684V mutations. Our studies show that proposed drug therapies offer a reasonable likelihood of controlling orthopoxvirus infections, even if the viruses encode drug resistance markers.",
author = "Graciela Andrei and Gammon, {Don B.} and Pierre Fiten and {De Clercq}, Erik and Ghislain Opdenakker and Robert Snoeck and Evans, {David H.}",
year = "2006",
month = "10",
day = "1",
doi = "10.1128/JVI.00605-06",
language = "English (US)",
volume = "80",
pages = "9391--9401",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "19",

}

TY - JOUR

T1 - Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice

AU - Andrei, Graciela

AU - Gammon, Don B.

AU - Fiten, Pierre

AU - De Clercq, Erik

AU - Opdenakker, Ghislain

AU - Snoeck, Robert

AU - Evans, David H.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC)] is recognized as a promising drug for the treatment of poxvirus infections, but drug resistance can arise by a mechanism that is poorly understood. We show here that in vitro selection for high levels of resistance to HPMPC produces viruses encoding two substitution mutations in the virus DNA polymerase (E9L) gene. These mutations are located within the regions of the gene encoding the 3′-5′ exonuclease (A314T) and polymerase (A684V) catalytic domains. These mutant viruses exhibited cross-resistance to other nucleoside phosphonate drugs, while they remained sensitive to other unrelated DNA polymerase inhibitors. Marker rescue experiments were used to transfer A314T and/or A684V alleles into a vaccinia virus Western Reserve strain. Either mutation alone could confer a drug resistance phenotype, although the degree of resistance was significantly lower than when virus encoded both mutations. The A684V substitution, but not the A314T change, also conferred a spontaneous mutator phenotype. All of the HPMPC-resistant recombinant viruses exhibited reduced virulence in mice, demonstrating that these E9L mutations are inextricably linked to reduced fitness in vivo. HPMPC, at a dose of 50 mg/kg of body weight/day for 5 days, still protected mice against intranasal challenge with the drug-resistant virus with A314T and A684V mutations. Our studies show that proposed drug therapies offer a reasonable likelihood of controlling orthopoxvirus infections, even if the viruses encode drug resistance markers.

AB - Cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC)] is recognized as a promising drug for the treatment of poxvirus infections, but drug resistance can arise by a mechanism that is poorly understood. We show here that in vitro selection for high levels of resistance to HPMPC produces viruses encoding two substitution mutations in the virus DNA polymerase (E9L) gene. These mutations are located within the regions of the gene encoding the 3′-5′ exonuclease (A314T) and polymerase (A684V) catalytic domains. These mutant viruses exhibited cross-resistance to other nucleoside phosphonate drugs, while they remained sensitive to other unrelated DNA polymerase inhibitors. Marker rescue experiments were used to transfer A314T and/or A684V alleles into a vaccinia virus Western Reserve strain. Either mutation alone could confer a drug resistance phenotype, although the degree of resistance was significantly lower than when virus encoded both mutations. The A684V substitution, but not the A314T change, also conferred a spontaneous mutator phenotype. All of the HPMPC-resistant recombinant viruses exhibited reduced virulence in mice, demonstrating that these E9L mutations are inextricably linked to reduced fitness in vivo. HPMPC, at a dose of 50 mg/kg of body weight/day for 5 days, still protected mice against intranasal challenge with the drug-resistant virus with A314T and A684V mutations. Our studies show that proposed drug therapies offer a reasonable likelihood of controlling orthopoxvirus infections, even if the viruses encode drug resistance markers.

UR - http://www.scopus.com/inward/record.url?scp=33748946630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748946630&partnerID=8YFLogxK

U2 - 10.1128/JVI.00605-06

DO - 10.1128/JVI.00605-06

M3 - Article

C2 - 16973545

AN - SCOPUS:33748946630

VL - 80

SP - 9391

EP - 9401

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 19

ER -